Showing 4121-4130 of 10903 results for "".
- Site Aims to Steer Patients to Physicians' Informationhttps://practicaldermatology.com/news/20130401-site_aims_to_steer_patients_to_physicians_information/2459577/Giving patients the proper information has always been important for physicians, and accessible handout literature has been the easiest ways to keep bad information out of their hands. But to keep pace with how quickly patients get their information, Vivacare allows physicians to enroll online free
- Two L'Oreal Brands at Select Walgreenshttps://practicaldermatology.com/news/20120824-two_loreal_brands_at_select_walgreens/2459745/
- Cosmetic Surgery Forum Offering Early Bird Rateshttps://practicaldermatology.com/news/20120820-cosmetic_surgery_forum_offering_early_bird_rates/2459750/
- Healthcare Spending Growth Expected to Remain Lowhttps://practicaldermatology.com/news/20120603-healthcare_spending_growth_expected_to_remain_low/2459793/
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- Early Emollient Therapy Linked to Lower Atopic Dermatitis Prevalence at Age 5https://practicaldermatology.com/news/early-emollient-therapy-linked-to-lower-atopic-dermatitis-prevalence-at-age-5/2488916/Early, short-term emollient therapy initiated shortly after birth was associated with lower atopic dermatitis (AD) prevalence and severity at age 5 years among high-risk children, according to long-term findings from the STOP-AD randomized controlled trial published in Pediatric Allergy and Immun
- FDA Approves Tildrakizumab for Adults With Active Psoriatic Arthritishttps://practicaldermatology.com/news/fda-approves-tildrakizumab-for-adults-with-active-psoriatic-arthritis/2488879/The US Food and Drug Administration (FDA) has approved tildrakizumab-asmn (ILUMYA; Sun Pharmaceutical Industries) for the treatment of adults with active psoriatic arthritis (PsA), according to an announcement from the company. The approval expands the use of the IL-23 inhibitor, which was
- Analysis: Estrogen Therapy Linked to Twofold Higher Odds of Porphyria Cutanea Tardahttps://practicaldermatology.com/news/analysis-estrogen-therapy-linked-to-twofold-higher-odds-of-porphyria-cutanea-tarda/2488877/New research published in JAMA Dermatology finds an association between estrogen-containing therapies and porphyria cutanea tarda, with differences observed by administration route. Researchers on the study examined whether estrogen exposure was associated with new PCT diagnoses a
- Analysis: Fewer Than Half of Patients With Multisite Mucous Membrane Pemphigoid Achieve Complete Remissionhttps://practicaldermatology.com/news/fewer-than-half-of-patients-with-multisite-mucous-membrane-pemphigoid-achieve-complete-remission/2488854/A retrospective study published in JAMA Dermatology indicated fewer than half of patients with multisite mucous membrane pemphigoid (MMP) achieved simultaneous complete remission across all affected sites, despite widespread improvement with treatment. Researchers at the
- Phase 3 Trial of Oral Minoxidil Formulation Meets Primary Endpoints in Male Pattern Hair Losshttps://practicaldermatology.com/news/phase-3-trial-of-oral-minoxidil-formulation-meets-primary-endpoints-in-male-pattern-hair-loss/2488751/Veradermics announced positive topline results from its Phase 3 Study 304 evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate androgenetic alopecia. The randomized, double-blind, placebo-controlled trial met both co-primary endpoints at